Dual WEE1 and JAK Inhibition Shows Promise Against Aggressive T-Cell Leukemias and Lymphomas
Mining genetic data from 1,825 patients, researchers found WEE1 inhibitors plus ruxolitinib synergistically kill JAK/STAT-driven T-cell cancer cells, including T-PLL samples.
Résumé
Mature T-cell leukemias and lymphomas are aggressive cancers with poor outcomes and few targeted options. Researchers assembled genetic data from 1,825 patients and ran it through a molecular tumor board bioinformatic tool to suggest matched drugs. They then screened 70 candidate drugs across 22 T-cell lymphoma cell lines. Inhibitors of WEE1 and CHK1, key cell-cycle and DNA damage response regulators, were broadly cytotoxic. The WEE1 inhibitor adavosertib caused replication stress, premature mitotic entry, DNA damage, and apoptosis, regardless of TP53 status. Combining it with the JAK inhibitor ruxolitinib was most synergistic in cell lines with active JAK/STAT signaling, and the combination also showed activity in patient T-PLL samples. These preclinical findings provide a rationale for clinical testing of this combination in genetically defined subtypes.
Résumé détaillé
Most mature T-cell leukemias and lymphomas (mTCL), including peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma and T-cell prolymphocytic leukemia (T-PLL), have poor prognoses. Anthracycline-based chemotherapy or alemtuzumab cures only a minority of patients, and relapsed disease is especially hard to treat. Better molecularly guided strategies are therefore urgently needed.
The team built a database of genetic alterations from 1,825 patients across 10 mTCL subtypes, compiled from landmark publications. They annotated it with the MTB-Report tool, a bioinformatic system developed in Göttingen to support molecular tumor boards. TET2 was the most commonly mutated gene (19%), followed by TP53, and JAK/STAT pathway genes (STAT3, STAT5B, JAK1, JAK3) were frequently altered. The tool identified potential therapeutics for 60% of patients, recommending 438 compounds in 76 drug classes. WEE1 inhibitors stood out as suggestions across all subtypes.
Seventy candidate drugs were screened across 22 genetically characterized mTCL cell lines. Responses were heterogeneous, with expected findings such as crizotinib activity in ALK-positive anaplastic large cell lymphoma. Inhibitors of WEE1 (adavosertib) and CHK1 (rabusertib) were cytotoxic in 20 of 22 lines, supported by an earlier genome-wide CRISPR screen. Adavosertib caused G2/M accumulation, premature mitotic entry, reduced CDC2 Tyr15 phosphorylation, and increased γH2AX and phospho-RPA32, indicating replication stress and DNA damage. Sensitivity did not depend on TP53 status but was higher in cells with damaging alterations in DDR genes (ATM, NBN, ATR, CHEK1, RPA1, RPA2).
In combination screens, ruxolitinib was the most robust partner for adavosertib, giving synergy in 3 of 4 lines and in about two-thirds of 11 lines tested. Synergy was strongest in lines with activating JAK1/2/3 alterations or STAT3 phosphorylation. Ruxolitinib downregulated cell-cycle, DNA replication and DDR gene sets, induced p27 and partial G1 arrest, and the combination increased cell death in G1 and S phases. BH3 profiling showed increased apoptotic priming and greater cytochrome c release with the combination. Methods also describe a MyLa xenograft model and ex vivo testing of 13 T-PLL patient samples, and the abstract reports synergy in primary T-PLL samples.
The work offers a blueprint for testing WEE1 plus JAK inhibition in patients with altered JAK/STAT signaling. Caveats include the reliance on cell lines, small sample sizes for ex vivo work, and the lack of clinical data. The provided text is truncated, so in vivo and primary-sample results cannot be fully assessed here.
Principales conclusions
- A database of 1,825 mTCL patients yielded drug suggestions for 60% of cases, with WEE1 inhibitors recommended across all subtypes.
- WEE1 inhibitor adavosertib and CHK1 inhibitor rabusertib were cytotoxic in 20 of 22 T-cell lymphoma cell lines.
- Adavosertib caused replication stress, premature mitosis and DNA damage, with efficacy independent of TP53 mutation status.
- Adding ruxolitinib to adavosertib was synergistic in about two-thirds of cell lines, especially those with JAK/STAT activation.
- The combination enhanced apoptotic priming and cytochrome c release, and the abstract reports activity in primary T-PLL samples.
Méthodologie
Preclinical study combining a genetic database of 1,825 mTCL patients, MTB-Report bioinformatic annotation, and an in vitro screen of 70 drugs across 22 cell lines. Mechanistic work used flow cytometry, immunoblotting, RNA sequencing, and BH3 profiling, with validation in a MyLa xenograft model and ex vivo testing of 13 T-PLL patient samples.
Limites de l'étude
Evidence is preclinical, based mainly on cell lines, with a small number of primary T-PLL samples and a short xenograft experiment. The genetic database was compiled from heterogeneous published sources, and tool recommendations depend on existing knowledge bases. The supplied full text was truncated, so some in vivo and ex vivo details could not be reviewed.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :